Novartis AG reported strong financial results for the second quarter of 2025, with a notable net sales increase of 12% to USD 14.1 billion, compared to USD 12.5 billion in the same period last year.

Novartis shares jumped 4% in overnight trading.

The growth was primarily driven by volume increases contributing 12 percentage points. The company faced a 2 percentage point negative impact from generic competition, while pricing and currency exchange effects each contributed a positive 1 percentage point.

The operational performance was robust, with the operating income rising 21% to USD 4.9 billion, up from USD 4.0 billion in the previous year.

This increase was mainly due to higher net sales, partially offset by investments in priority brands, new product launches, and legal expenses.

Net income for the quarter reached USD 4.0 billion, a 24% increase from the previous year's USD 3.2 billion. Earnings per share also saw a substantial rise, reaching USD 2.07, up 29% from USD 1.60 in the second quarter of 2024.

Significant advancements were made in Novartis's product pipeline, including a third positive Phase III result for Pluvicto in hormone-sensitive prostate cancer and global regulatory submissions for OAV101. The company continues to focus on its portfolio's renewal potential, leveraging successful new launches of products like Kisqali, Pluvicto, and Scemblix.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001118316-de) on July 17, 2025, and is solely responsible for the information contained therein.